Literature DB >> 608659

Malignant neuroleptic syndrome--its present status in Japan and clinical problems.

H Itoh, N Ohtsuka, K Ogita, G Yagi, S Miura, Y Koga.   

Abstract

Fourteen cases in which hyperpyrexia, akinesia, mutism, extrapyramidal symptoms and severe, diverse autonomic symptoms developed in the course of neuroleptic drug therapy are reported as the malignant neuroleptic syndrome, with analysis and discussion of the clinical features and pathogenic factors. Possible factors contributing to the danger of evoking this syndrome are: 1. Physical exhaustion associated with dehydration, and 2. Parenteral administration of neuroleptic agents, especially of the incisive type. Symptomatologic similarity of the syndrome to the condition known as malignant hyperthermia during anesthesia is also discussed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 608659

Source DB:  PubMed          Journal:  Folia Psychiatr Neurol Jpn        ISSN: 0015-5721


  9 in total

1.  Risk factors in neuroleptic malignant syndrome.

Authors:  Vinay Gupta; Rakesh Magon; B P Mishra; G B S Sidhu; Ranjiv Mahajan
Journal:  Indian J Psychiatry       Date:  2003-01       Impact factor: 1.759

2.  Muscle pathology in the neuroleptic malignant syndrome.

Authors:  D T Martin; M Swash
Journal:  J Neurol       Date:  1987-12       Impact factor: 4.849

Review 3.  Neuroleptic malignant syndrome.

Authors:  G A Chaimowitz; U Gomes; S S Maze
Journal:  CMAJ       Date:  1988-01-01       Impact factor: 8.262

4.  Neuroleptic malignant syndrome.

Authors:  E Szabadi
Journal:  Br Med J (Clin Res Ed)       Date:  1984-05-12

5.  Neuroleptic malignant syndrome: a complication of neuroleptics and cocaine abuse.

Authors:  M J Akpaffiong; P Ruiz
Journal:  Psychiatr Q       Date:  1991

6.  Differences between antipsychotic drugs in persistence of brain levels and behavioral effects.

Authors:  B M Cohen; T Tsuneizumi; R J Baldessarini; A Campbell; S M Babb
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 7.  Neuroleptic malignant syndrome.

Authors:  M S Jahan; A I Farooque; Z Wahid
Journal:  J Natl Med Assoc       Date:  1992-11       Impact factor: 1.798

8.  Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome.

Authors:  Daiji Kato; Chiaki Kawanishi; Ikuko Kishida; Taku Furuno; Kyoko Suzuki; Hideki Onishi; Yoshio Hirayasu
Journal:  Eur J Clin Pharmacol       Date:  2007-08-14       Impact factor: 2.953

Review 9.  Antipsychotic dose escalation as a trigger for neuroleptic malignant syndrome (NMS): literature review and case series report.

Authors:  Julie Langan; Daniel Martin; Polash Shajahan; Daniel J Smith
Journal:  BMC Psychiatry       Date:  2012-11-29       Impact factor: 3.630

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.